Cheng G, Hardy M, You M, Kalyanaraman B. Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. Sci Rep 2022;12:5143. [PMID: 35332210 DOI: 10.1038/s41598-022-08984-6][Reference Citation Analysis]
Kalyanaraman B. Reactive oxygen species, proinflammatory and immunosuppressive mediators induced in COVID-19: overlapping biology with cancer. RSC Chem Biol 2021;2:1402-14. [PMID: 34704045 DOI: 10.1039/d1cb00042j][Reference Citation Analysis]
4
Kalyanaraman B. Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research. FASEB J 2022;36:e22226. [PMID: 35233843 DOI: 10.1096/fj.202101862R][Reference Citation Analysis]